Abstract
Background
The enhancement overlaps at contrast-enhanced mammogram (CEM) between benign and malignant breast abnormalities presents a high probability of false-positive lesions and subjects females’ candidate for screening and diagnostic mammograms to unnecessary biopsy and anxiety. The current work aimed to evaluate the ability of mammograms scanned by artificial intelligence (AI) to enhance the specificity of CEM and support the probability of malignancy in suspicious and malignant looking breast lesions.
Methods
The study included 1524 breast lesions. The AI algorithm applied to the initial mammograms and generated location information for lesions. AI scoring suggested the probability of malignancy ranged from 100% (definite cancers) and < 10% (definite non-cancer) and correlated with recombinant contrast enhanced images.
Results
The malignant proved abnormalities were 1165 (76.5%), and the benign ones were 359 (26.5%). BI-RADS 4 category was assigned in 704 lesions (46.2%) divided into 400 malignant (400/704, 56.8%) and 304 benign (304/704, 43.2%). BI-RADS 5 category presented by 820 lesions (53.8%), 765 of them were malignant (765/820, 93.3%) and 55 were benign (55/820, 6.7%). The sensitivity of digital mammogram whether supported by AI (93.9%) or contrast media (94.4%) was significantly increased to 97.2% (p < 0.001) when supported by both methods. Improvement of the negative predictive value (from 80.6% and 79.6% to 89.8%, p < 0.05) and the accuracy (from 91.1 and 88.8 to 94.0%, p < 0.01) was detected.
Conclusions
Contrast-enhanced mammogram helps in specification of different breast lesions in view of patterns of contrast uptake and morphology descriptors, yet with some overlap. The use of artificial intelligence applied on digital mammogram reduced the interpretational variability and limited attempts of re-biopsies of suspicious looking breast lesions assessed by contrast-enhanced mammograms.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Azzam, Heba 1 ; El-Assaly, Hany 2 1 Cairo University, Women’s Imaging Unit, Radiology Department, Kasr El Ainy Hospital, Cairo, Egypt (GRID:grid.7776.1) (ISNI:0000 0004 0639 9286); Baheya center for early breast cancer and treatment, Radiology Department, Cairo, Egypt (GRID:grid.7776.1)
2 Cairo University, Women’s Imaging Unit, Radiology Department, Kasr El Ainy Hospital, Cairo, Egypt (GRID:grid.7776.1) (ISNI:0000 0004 0639 9286)





